Cell Therapeutics initiates launch of Pixuvri in Europe

12 September 2012

Following the European approval of the drug this spring (The Pharma Letter May 14), US biotech firm Cell Therapeutics (Nasdaq and MTA: CTIC) has initiated the commercial launch of Pixuvri (pixantrone) in the European Union, with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, the UK and the Netherlands in November 2012.

Cell Thera plans to expand availability to France, Italy and Spain as well as other European countries in 2013. Pixuvri is the first medicinal product licensed in the EU to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). In the EU, there are about 37,000 new cases of aggressive B-cell NHL every year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >